HomeProductsBuilding BlocksHeterocyclic ScaffoldsBenzimidazolesGaleterone
Chemical structure of CAS 851983-85-2

Galeterone

CAS No.851983-85-2
MDL No.MFCD16660907
MFC26H32N2O
MW388.50
InChI KeyPAFKTGFSEFKSQG-PAASFTFBSA-N
CUSTOM SYNTHESIS

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Galeterone is a 3-hydroxy steroid with androgen activity.

CAS No.851983-85-2
Product NameGaleterone

Biological Targets

AR·CYP17A1

Associated Conditions

prostate cancer·Malignant Pancreatic Neoplasm
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

BMC urology • Vol. 14 • 2014
PMID: 25062956PMC: PMC4167156DOI: 10.1186/1471-2490-14-55

CYP17 inhibitors for prostate cancer therapy.

The Journal of steroid biochemistry and molecular biology • Vol. 125, Issue 1-2 • 2011
PMID: 21092758PMC: PMC3047603DOI: 10.1016/j.jsbmb.2010.11.005

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Molecular cancer therapeutics • Vol. 7, Issue 8 • 2008
PMID: 18723482PMC: PMC2643345DOI: 10.1158/1535-7163.MCT-08-0230

CYP17 inhibition as a hormonal strategy for prostate cancer.

Nature clinical practice. Urology • Vol. 5, Issue 11 • 2008
PMID: 18985049DOI: 10.1038/ncpuro1237

Documentation

Similar Products